Disclosures
Stefan M. Pulst, MD
Scientific Advisory Boards
National Ataxia Foundation, Medical Research Advisory Board Hertie Institute for Brain Science, University of Tuebingen
Editorial Boards
Nature Clinical Practice Neurology; Editor: Neurology® Genetics
Patents
Nucleic acids encoding ataxin-2 binding proteins; Nucleic acid encoding Schwannomin-binding-proteins and products related thereto; Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide; Methods of detecting spinocerebellar ataxia-2 nucleic acids; Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto; Schwannomin-binding-proteins; Compositions and methods for spinocerebellar ataxia; Methods For Modulating Ataxin2 Expression
Publishing Royalties
The Ataxias (Churchill Livingston, 2007), Genetics in Neurology (ANN Press, 2005), Genetics of Movement Disorders (Academic Press, 2003), Neurogenetics (Oxford University Press, 2000), Molecular Genetic Testing in Neurology, 2nd - 5th (AAN Press, 1996)
Research Support, Government Entities
2014-2021 National Institutes of Health (R37NS33123): Spinocerebellar ataxia type 2: gene and gene product. 9/30/14-6/30/2021. (Principal Investigator). 2018-2020 Harrington Discovery Institute Harrington Rare Disease Award: Development of a therapeutic for SCA2 and other rare neurodegenerative diseases. 3/1/18-2/28/20. Co-Investigator (Principal Investigator: D. Scoles) 2014-2021 National Institutes of Health Senator Jacob Javits Merit Award (R37 NS033123): Spinocerebellar ataxia type 2: gene and gene product. 10/1/14-6/30/21. Principal Investigator 2017-2020 National Institutes of Health (R21 NS104799-01): Deep cerebellar stimulation to treat degenerative cerebellar ataxia. 9/1/17-8/31/20. Principal Investigator 2017-2022 National Institutes of Health (R01 NS097903): RNA granules in cerebellar neurodegeneration. 4/1/17-3/31/22. Co-Investigator (Principal Investigator: D. Scoles) 2018-2021 National Institute of Neurological Disorders and Stroke (U01 NS103883): Antisense Oligonucleotides for treating spinocerebellar ataxia type 2. 2/15/18-1/31/21. Principal Investigator (with D. Scoles) 2018-2023 National Institute of Neurological Disorders and Stroke (U01 NS104326): Clinical Trial readiness for SCA1 and SCA3. 1/1/18-12/31/2023. Site Investigator (Principal Investigator: T. Ashizawa) 2018-2020 National Institute of Neurological Disorders and Stroke (R21NS103009): Characterization of ATXN2 as a target for ALS in SCA2 motor neurons. 7/1/18-6/30/21. Principal Investigator. 2019-2024 National Institute of Neurological Disorders and Stroke (R01 NS085054): Identifying symptomatic and neuroprotective strategies for cerebellar ataxia. 4/15/2019-3/31/2024. Site Investigator (Principal Investigator: V. Shakkottai) 2020-2023 CYDAN: SCA1 and SCA2 Studies With Cck1 Receptor Agonist. 1/1/2020-12/31/23. Principal Investigator
License fee payments, Technology or Inventions
University of Utah (license for invention & technologies
Royalty Payments, Technology or Inventions
University of Utah